Related Experiment Video

Updated: Oct 6, 2025

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.5K

Is CD25 blockade optimal in kidney transplant patients treated with basiliximab? A target-mediated drug disposition

Olivier Le Tilly1,2, Philippe Gatault1,3, Christophe Baron1,3

  • 1EA 4245 «Transplantation, Immunology, Inflammation», Université de Tours, Tours, France.

British Journal of Clinical Pharmacology
|January 19, 2022
PubMed
Abstract

Insights

Basiliximab, an anti-CD25 antibody, has nonlinear elimination influenced by target levels. Cyclosporine may lower CD25 levels, suggesting optimized dosing could enhance basiliximab efficacy in kidney transplant patients.

Area of Science:

  • Pharmacology
  • Immunology
  • Nephrology

Background:

  • Basiliximab is an anti-CD25 chimeric monoclonal antibody used to prevent acute kidney transplant rejection.
  • Understanding its pharmacokinetic profile is crucial for optimizing therapeutic outcomes.

Purpose of the Study:

  • To investigate the target-mediated pharmacokinetics of basiliximab.
  • To describe the nonlinear elimination of basiliximab based on CD25 antigen levels.

Main Methods:

  • Reanalysis of data from the IDEALE study involving 16 kidney transplant patients.
  • Application of a population 2-compartment target-mediated drug disposition model with quasi-steady-state approximation.

Main Results:

  • Basiliximab pharmacokinetics exhibited significant differences in volume of distribution between males.
  • Lower estimated baseline CD25 antigen levels were observed in patients co-treated with cyclosporine.

Conclusions:

  • This study provides the first description of target-mediated nonlinear elimination of basiliximab.
  • Cyclosporine co-treatment is associated with decreased CD25 target levels, indicating potential for optimized dosing regimens to improve basiliximab effects.
Keywords:
CD25basiliximabcyclosporinekidney transplantationmonoclonal antibodypharmacokineticstarget-mediated drug disposition

More Related Videos

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.3K
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.1K

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
70
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
87
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
4